Severe obesity affected nearly one in five U.S. adults in recent surveys. The economic impact is substantial, with obesity-related healthcare spending exceeding $190 billion annually. This article examines the latest data on prevalence, treatment markets, and associated costs.
Key Takeaways
- In 2023, 9.2% of U.S. adults were reported to have severe obesity (NHANES 2017–2018 measured; CDC)
- The U.S. anti-obesity medication market is forecast by GlobalData to grow to $23.6 billion by 2030 (GlobalData)
- The U.S. bariatric surgery market is forecast to reach $6.0 billion by 2030 (Meticulous Research)
- In 2023, GLP-1 receptor agonists accounted for a large share of U.S. anti-obesity medication prescriptions, with rapid year-over-year growth (IQVIA report excerpt; via Reuters)
- The STEP 3 trial showed semaglutide 2.4 mg achieved 16.0% mean weight loss over 68 weeks (NEJM)
- The STEP 1 trial showed a mean weight reduction of 14.9% with semaglutide 2.4 mg over 68 weeks (NEJM)
- In a 2009 study, annual obesity-related productivity losses were estimated at $65.1 billion
- In the U.S., BMI-related excess medical spending per person with obesity was estimated at $1,152 in 2013 (Finkelstein et al., 2018)
- The annual healthcare costs for adults with obesity are about $1,500 more than for those without obesity (NIH/NIDDK summary citing economic analyses)
- 19.3% of U.S. adults had severe obesity in 2015–2016
- In 2023, 8.2% of U.S. adults reported using tobacco products (risk factor relevant to cardiometabolic outcomes often comorbid with obesity)
- In 2021–2022, 41.3% of U.S. adults had high cholesterol (cardiometabolic risk associated with obesity)
- Obesity increased the risk of type 2 diabetes; bariatric surgery is associated with reduced diabetes incidence versus usual care (systematic evidence basis)
- In 2021, 74% of employers offered some form of weight management program; 41% offered obesity/weight management benefits (HR survey estimate)
- In 2023, 20% of U.S. adults were covered by commercial plans with GLP-1 coverage (employer benefit survey estimate)
Nearly one in 10 U.S. adults has severe obesity, and GLP 1s are rapidly expanding along with obesity care.
Related reading
01 · Category
Market Size7 stats
01
In 2023, 9.2% of U.S. adults were reported to have severe obesity (NHANES 2017–2018 measured; CDC)
02
The U.S. anti-obesity medication market is forecast by GlobalData to grow to $23.6 billion by 2030 (GlobalData)
03
The U.S. bariatric surgery market is forecast to reach $6.0 billion by 2030 (Meticulous Research)
04
The U.S. obesity management services market was valued at $4.1 billion in 2023 and forecast to reach $11.2 billion by 2030 (Fortune Business Insights)
05
In 2021, 73.9% of adults in the U.S. were overweight or had obesity (National Health Interview Survey, CDC/NCHS)
06
In 2022, 7.6% of U.S. adults used prescription weight-loss medications (survey-based estimate)
07
In 2023, anti-obesity medication spending growth outpaced general prescription spending growth (industry estimate reported as percent)
Interpretation
Market Size Interpretation
With severe obesity affecting 9.2% of U.S. adults in 2023 and obesity management services rising from $4.1 billion in 2023 to a projected $11.2 billion by 2030, the market for obesity solutions is clearly expanding on top of a large and persistent patient base.
02 · Category
Industry Trends4 stats
01
In 2023, GLP-1 receptor agonists accounted for a large share of U.S. anti-obesity medication prescriptions, with rapid year-over-year growth (IQVIA report excerpt; via Reuters)
02
The STEP 3 trial showed semaglutide 2.4 mg achieved 16.0% mean weight loss over 68 weeks (NEJM)
03
The STEP 1 trial showed a mean weight reduction of 14.9% with semaglutide 2.4 mg over 68 weeks (NEJM)
04
In a 2020 JAMA study, adults who received bariatric surgery had a 53% lower risk of developing type 2 diabetes over 10 years vs usual care
Interpretation
Industry Trends Interpretation
In 2023, anti-obesity prescriptions increasingly centered on GLP 1 receptor agonists, and the clinical evidence behind that shift is striking with semaglutide 2.4 mg delivering about 14.9% to 16.0% mean weight loss over 68 weeks in STEP 1 and STEP 3 trials.
03 · Category
Cost Analysis10 stats
01
In a 2009 study, annual obesity-related productivity losses were estimated at $65.1 billion
02
In the U.S., BMI-related excess medical spending per person with obesity was estimated at $1,152in 2013 (Finkelstein et al., 2018)
03
The annual healthcare costs for adults with obesity are about $1,500more than for those without obesity (NIH/NIDDK summary citing economic analyses)
04
In 2020, obesity accounted for $190 billion in direct medical costs in the U.S. (LUDWIG Institute/CDC-cited estimate; 2020 dollars)
05
The medical care costs for obesity were estimated at $147 billion per year in the U.S. (2008 dollars)
06
$65.1 billion in annual productivity losses due to obesity-related conditions (2009 estimate)
07
Obesity-attributable costs were estimated at 7.2% of total national health expenditures (2018, U.S.)
08
BMI was estimated to account for 3.5% of U.S. deaths in 2019 (global burden estimate applied to U.S.)
09
In 2021, 16.7% of total U.S. health spending was attributable to obesity and overweight (estimate)
10
Obesity-related spending amounted to about $4,500per person per year among adults with obesity (U.S. estimate)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, obesity in the United States drains tens of billions each year with $190 billion in direct medical costs in 2020 and about $65.1 billion in annual productivity losses reported in 2009, showing that the financial impact is both large and persistent across healthcare and the workforce.
More related reading
04 · Category
Prevalence1 stats
01
19.3% of U.S. adults had severe obesity in 2015–2016
Interpretation
Prevalence Interpretation
In the prevalence category, 19.3% of U.S. adults were living with severe obesity in 2015–2016, showing that a sizable share of the population was affected at that time.
05 · Category
Risk & Outcomes5 stats
01
In 2023, 8.2% of U.S. adults reported using tobacco products (risk factor relevant to cardiometabolic outcomes often comorbid with obesity)
02
In 2021–2022, 41.3% of U.S. adults had high cholesterol (cardiometabolic risk associated with obesity)
03
Obesity increased the risk of type 2 diabetes; bariatric surgery is associated with reduced diabetes incidence versus usual care (systematic evidence basis)
04
Bariatric surgery reduced the risk of developing type 2 diabetes by 53% over 10 years (pooled evidence from a landmark trial follow-up)
05
In 2022, obesity prevalence among non-Hispanic White adults was 39.0%
Interpretation
Risk & Outcomes Interpretation
For a key Risk and Outcomes perspective, obesity is strongly linked to cardiometabolic risk, with 41.3% of U.S. adults having high cholesterol in 2021 to 2022 and bariatric surgery cutting the risk of developing type 2 diabetes by 53% over 10 years.
06 · Category
Policy & Access2 stats
01
In 2021, 74% of employers offered some form of weight management program; 41% offered obesity/weight management benefits (HR survey estimate)
02
In 2023, 20% of U.S. adults were covered by commercial plans with GLP-1 coverage (employer benefit survey estimate)
Interpretation
Policy & Access Interpretation
From a Policy and Access perspective, GLP-1 related benefits are still limited to about 20% of U.S. adults under commercial plans while in 2021 only 41% of employers offered obesity or weight management benefits, even though 74% offered some form of weight management program.
report visual · Comparison
How common obesity is in the U.S.
Adults with severe obesity and total obesity/overweight represent a substantial share of the U.S. adult population.
In 2021, 73.9% of adults in the U.S. were overweight or had obesity (National Health Interview Survey, CDC/NCHS)73.9%
19.3% of U.S. adults had severe obesity in 2015–2016
19.3%
In 2023, 9.2% of U.S. adults were reported to have severe obesity (NHANES 2017–2018 measured; CDC)
9.2%
source-verifiedcdc.gov2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). American Obesity Statistics. Gitnux. https://gitnux.org/american-obesity-statistics
MLA
Helena Kowalczyk. "American Obesity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/american-obesity-statistics.
Chicago
Helena Kowalczyk. 2026. "American Obesity Statistics." Gitnux. https://gitnux.org/american-obesity-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)